Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

被引：0
|
作者：
Rubin, David T. [1 ]
Cree, Bruce A. C. [2 ]
Wolf, Douglas C. [3 ]
Alekseeva, Olga [4 ]
Charles, Lorna [5 ]
Petersen, AnnKatrin [5 ]
Sheffield, James K. [5 ]
Cheng, Chun-Yen [5 ]
Riolo, Jon V. [5 ]
Silva, Diego [5 ]
Lublin, Fred D. [6 ]
Cohen, Jeffrey A. [7 ]
Danese, Silvio [8 ]
机构：
[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[2] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA USA
[3] Atlanta Gastroenterol Associates, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[4] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Nizhegorod, Russia
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Mt Sinai Med Ctr, New York, NY USA
[7] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA
[8] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Milan, Lombardia, Italy
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S911
引用
下载
收藏
页码：S680 / S680
页数：1
相关论文
共 50 条
  • [31] LONG-TERM SAFETY OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    Hauser, Stephen
    Cross, Anne
    Winthrop, Kevin
    Wiendl, Heniz
    Nicholas, Jacqueline
    Meuth, Sven
    Giacomini, Paul
    Sacca, Francesco
    Su, Wendy
    Kappos, Ludwig
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [32] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [33] Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B. G.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S6 - S7
  • [34] Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension
    Gibson, Peter R.
    Reinisch, Walter
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen W.
    Strauss, Richard
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2014, 146 (05) : S587 - S587
  • [35] Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
    Taxonera, Carlos
    Iborra, Marisa
    Maia Bosca-Watts, Marta
    Rubio, Saioa
    Nantes, Oscar
    Higuera, Rebeca
    Bertoletti, Federico
    Martinez-Montiel, Pilar
    Sierra-Ausin, Monica
    Mancenido, Noemi
    Lazar Perez-Calle, Jose
    Algaba, Alicia
    Olivares, David
    Alba, Cristina
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1297 - 1304
  • [36] Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William J.
    Feagan, Brian G.
    Strauss, Richard
    Johanns, Jewel
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul
    Tarabar, Dino
    Marano, Colleen
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (09): : 1053 - 1066
  • [37] INCIDENCE OF INFECTIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD AND RELATIONSHIP TO SIGNIFICANT LYMPHOPENIA: RESULTS FROM A POOLED SAFETY ANALYSIS
    Rieder, Florian
    Wolf, Douglas C.
    Charles, Lorna
    Kollengode, Kanthi
    Hsu, Kate
    Patel, Aditya
    Ghosh, Subrata
    GASTROENTEROLOGY, 2021, 160 (06) : S339 - S340
  • [38] CLINICAL REMISSION DEMONSTRATED WITH ORAL OZANIMOD IN THE OVERALL POPULATION AND ACROSS MULTIPLE SUBGROUPS OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE TOUCHSTONE TRIAL
    Feagan, Brian G.
    Sandborn, William J.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Wolf, Douglas C.
    Vermeire, Severine
    Ghosh, Subrata
    Petersen, AnnKatrin
    Hua, Steven
    Shan, Kevin
    Liu, Jerry
    GASTROENTEROLOGY, 2019, 156 (06) : S1103 - S1104
  • [39] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Krakovich, A.
    Sheffield, J. K.
    Cheng, C. -Y.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
  • [40] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
12345